Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican
Autor: | Thomas Muley, Stefan Günther, Hauke Winter, Werner Seeger, Mark Kriegsmann, Kati Turkowski, Friedrich Grimminger, Reinhard Dammann, Soni Savai Pullamsetti, Andreas Weigert, Andreas Guenther, Rajkumar Savai, David Brunn, Georgios T. Stathopoulos, Michael Thomas |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Cancer Research Response element versican (VCAN) medicine.disease_cause lcsh:RC254-282 Article Adenocarcinoma Interferon Regulatory Factor 9 (irf9) Lung Cancer Tumor Microenvironment (tme) Type I Interferons (ifns) Versican (vcan) 03 medical and health sciences 0302 clinical medicine Interferon medicine ddc:610 tumor microenvironment (TME) interferon regulatory factor 9 (IRF9) Transcription factor Gene knockdown Tumor microenvironment adenocarcinoma biology lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens lung cancer 030104 developmental biology Oncology 030220 oncology & carcinogenesis type I interferons (IFNs) Cancer research biology.protein Versican Carcinogenesis Interferon regulatory factors medicine.drug |
Zdroj: | Cancers Cancers, Vol 13, Iss 208, p 208 (2021) Volume 13 Issue 2 Cancers 13:208 (2021) |
ISSN: | 2072-6694 |
Popis: | Transcription factors can serve as links between tumor microenvironment signaling and oncogenesis. Interferon regulatory factor 9 (IRF9) is recruited and expressed upon interferon stimulation and is dependent on cofactors that exert in tumor-suppressing or oncogenic functions via the JAK-STAT pathway. IRF9 is frequently overexpressed in human lung cancer and is associated with decreased patient survival however, the underlying mechanisms remain to be elucidated. Here, we used stably transduced lung adenocarcinoma cell lines (A549 and A427) to overexpress or knockdown IRF9. Overexpression led to increased oncogenic behavior in vitro, including enhanced proliferation and migration, whereas knockdown reduced these effects. These findings were confirmed in vivo using lung tumor xenografts in nude mice, and effects on both tumor growth and tumor mass were observed. Using RNA sequencing, we identified versican (VCAN) as a novel downstream target of IRF9. Indeed, IRF9 and VCAN expression levels were found to be correlated. We showed for the first time that IRF9 binds at a newly identified response element in the promoter region of VCAN to regulate its transcription. Using an siRNA approach, VCAN was found to enable the oncogenic properties (proliferation and migration) of IRF9 transduced cells, perhaps with CDKN1A involvement. The targeted inhibition of IRF9 in lung cancer could therefore be used as a new treatment option without multimodal interference in microenvironment JAK-STAT signaling. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |